Immunology: A tolerant approach

Nature

Volumn 507, Issue 7493, 2014, Pages 418-420

  Garber, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BHT 3021; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

DISEASE CONTROL; DRUG; DRUG DEVELOPMENT; HEALTH RISK; IMMUNE RESPONSE;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL PROLIFERATION; DISEASE ACTIVITY; DRUG INDUSTRY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE;

COLORADO; UNITED STATES;

ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ACTIVE; MALE; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME; VACCINES;

EID: 84897378786     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/507418a     Document Type: Short Survey

References (12)

1. Getts, D. R. et al. J. Immunol. 187, 2405-2417 (2011).
2. Gabryšová, L. et al. J. Exp. Med. 206, 1755-1767 (2009).
3. Juryczyk, M. et al. Ann. Neurol. 68, 593-601 (2010).
4. Solvason, N. et al. J. Immunol. 181, 8298-8307 (2008).
5. Suntharalingam, G. et al. N. Engl. J. Med. 355, 1018-1028 (2006).
6. Bielekova, B. et al. Nature Med. 6, 1167-1175 (2000).
7. Freedman, M. S. et al. Neurology 77, 1551-1560 (2011).
8. McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C. & Miller, S. D. J. Exp. Med. 182, 75-85 (1995).
9. Lutterotti, A. et al. Sci. Transl. Med. 5, 188ra75 (2013).
10. Walczak, A., Siger, M., Ciach, A., Szczepanik, M. & Selmaj, K. J. Am. Med. Assoc. Neurol. 70, 1105-1109 (2013).
11. Roep, B. O. et al. Sci. Transl. Med. 5, 191ra82 (2013).
12. Getts, D. R. et al. Nature Biotechnol. 30, 1217-1224 (2012).